Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea Life Sciences HoldingsPLSH -25.00% Earnings Yield (Joel Greenblatt) % is 96.15% as of Sep. 2025. The stock has 10 warning signs investors should review. Among 1,013 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 98.72% on this metric.
Panacea Life Sciences Holdings's Enterprise Value for the quarter that ended in Sep. 2025 was $1.80 Mil.
Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $1.74 Mil. Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2025 was 96.15%.
The historical rank and industry rank for Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
PLSH'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53.01 Med: -24.22 Max: 107.53
Current: 95.24
During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of Panacea Life Sciences Holdings was 107.53%. The lowest was -53.01%. And the median was -24.22%.
PLSH's Earnings Yield (Joel Greenblatt) % is ranked better than 98.72% of 1013
companies
in the Drug Manufacturers industry
Industry Median: 3.29
vs PLSH: 95.24
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Panacea Life Sciences Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Earnings Yield (Joel Greenblatt) % falls into.
Panacea Life Sciences Holdings Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Panacea Life Sciences Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Panacea Life Sciences Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.74 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 96.15% mean?
Panacea Life Sciences Holdings (PLSH) has a Earnings Yield (Joel Greenblatt) % of 96.15% as of Sep. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #13 out of 1013 companies in the Drug Manufacturers industry, placing it in the top 1.3%.
Is Panacea Life Sciences Holdings' Earnings Yield (Joel Greenblatt) % too high?
Panacea Life Sciences Holdings' current Earnings Yield (Joel Greenblatt) % is 96.15%. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.29. Panacea Life Sciences Holdings' value of 96.15% is 2822.5% above this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #13 out of 1013 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Panacea Life Sciences Holdings' Earnings Yield (Joel Greenblatt) % compare to SKYI and IMCC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #13 out of 1013 companies for Earnings Yield (Joel Greenblatt) %. This places Panacea Life Sciences Holdings in the top 1% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.29. Panacea Life Sciences Holdings' value of 96.15% is 2822.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.29, based on 1,013 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Earnings Yield (Joel Greenblatt) % of 96.15% is 2822.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Earnings Yield (Joel Greenblatt) % is 96.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Earnings Yield (Joel Greenblatt) % of 96.15%. The current Earnings Yield (Joel Greenblatt) % is 96.15% and 2822.5% above the Drug Manufacturers industry median of 3.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Earnings Yield (Joel Greenblatt) % is 96.15% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Business Description
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
